arney complex (CNC), a neoplastic syndrome first characterized in 1985, consists of (1) myxomas in the heart and other locations (breast or skin), (2) spotty pigmentation (lentigines, pigmented nevi, or both), (3) endocrine overactivity (pituitary adenoma, primary pigmented nodular adrenocortical disease, or testicular tumors involving the endocrine components). 1 Although cardiac myxoma is the most common, usually benign, tumor of the heart, it can cause a critical clinical situation. We present a case of recurrent cardiac myoma that was identified as CNC with a genetic mutation.
Case Report
A 60-year-old Japanese male was referred for further evaluation of intracardiac mass in the right atrium. He had a past history of resection of a left atrial cardiac myxoma in 1992 (Fig 1A) , at which time he suffered a cerebral hemorrhage caused by multiple cerebral aneurysms from myxoma tissue embolism. Because some of those cerebral aneurysms were gradually increasing in size, a series of aneurysmectomies was successfully performed in November 1993 to prevent rupture. In 1998 acromegaly was noted in a routine medical follow up and magnetic resonance imaging revealed a pituitary microadenoma with a diameter of 3.0 mm, which was neurosurgically resected by a transsphenoidal approach. Thereafter he was asymptomatic and closely followed in an outpatient clinic while receiving bromocriptine. In January 2003 routine cardiac ultrasonography incidentally detected a new intracardiac tumor in the right atrium (Fig 1B) . He did not have a family history of cardiac myxoma or endocrinopathy.
During physical examination we observed acromegaly especially in the limbs and face. There were neither cardiac murmurs nor abnormal respiratory sounds. Remarkable skin pigmentation was noted. Blood tests showed slight elevation of the erythrocyte sedimentation rate and a significant increase in the interleukin-6 (IL6) concentration (81.9 pg/ml (normal range <4.0 pg/ml)), which is a useful biochemical marker of cardiac myxoma. 2 Preoperative cardiac catheterization revealed normal coronary arteries without evident tumor-feeding arteries and normal left ventricular function. All of these findings strongly suggested recurrent cardiac myxoma.
The intracardiac tumor was surgically resected and the pathological findings were compatible with myxoma. His postoperative course was uneventful and the IL6 concentration decreased significantly to 9.7 pg/ml. Since discharge, he has been leading a normal life and routine ultrasonographic studies have not revealed any sign of tumor recurrence.
The patient's recurrent cardiac myxomas, pituitary adenoma and skin pigmentation satisfy the clinical criteria for CNC. 3 Protein kinase A regulatory subunit 1 (PRKAR1A) has been identified as one of the causative genes of CNC, 4,5 so after obtaining written informed consent from the patient, we sequenced the 10 exons of PRKAR1A using DNA extracted from his blood. We identified one heterozygous base pair deletion in exon 2, which produced a frame shift and premature stop codon with consequent PRKAR1A haploinsufficiency (Fig 2) . This mutation site has not been reported in the literature. In addition, a base pair substitution (C to T) 3 base pairs downstream from the deletion site was also detected. The presence of a genetic mutation of PRKAR1A strongly supports our clinical diagnosis.
Discussion
Myxoma is the most common type of primary cardiac tumor, comprising 30-50% of the total in most pathological series. 6 Most myxomas occur in the left atrium and are usually attached to the fossa ovalis. However, myxomas may occasionally be found in the right atrium and, less often, the right or left ventricle. Some patients with cardiac myxoma have CNC. Syndromic myxomas, usually genetically transmitted, constitute approximately 10% or less of all myxomas. Patients with CNC tend to be younger and are more likely to have myxomas in locations other than left atrium.
Genetically, CNC is thought to be inherited in an autosomal dominant fashion and the responsible genes have been mapped to 2p16 and 17q22-24. 7 In the latter candidate locus, PRKAR1A has been identified as one of the causative genes for CNC. The R1 regulatory subunit binds to the catalytic subunits of protein kinase A, inactivating the holoenzyme PRKAR1A. Thus, genetic mutations of PRKAR1A cause an increase in cAMP-stimulated activity of protein kinase A, ultimately leading to tumorigenesis. In the present case there was a novel frame shift mutation in exon 2 of PRKAR1A, which is a 'hot spot' previously identified in several pedigrees of CNC. Unfortunately, further evaluation of genetic mutation in his family was impossible because he has neither children nor siblings. However, the lack of a family history of syndromic cardiac myxoma or endocrinopathy suggests sporadic occurrence.
Although cardiac myxoma is usually benign, tumor embolism, intracardiac obstruction or other neoplastic formation can cause a critical situation. Therefore, a genetic survey of PRKAR1A mutations in patients with cardiac myxoma will assist with clinical decision making. 
